Skip to main content
. Author manuscript; available in PMC: 2010 Jul 9.
Published in final edited form as: Cancer. 2008 Sep 15;113(6):1438–1445. doi: 10.1002/cncr.23775

TABLE 3.

Persistent Use of Zoledronic Acid Was Associated With Longer Follow-up Duration*

Treatment Persistency, d* Follow-Up Duration, mo
Untreated 8.7
31–90 9.6
91–180 11.5
181–365 14.8
>365 22.6
*

Treatment persistency was defined as the absence of a gap >45 days between zoledronic acid treatments.